Brain Tumor Clinical Trials

Find Brain Tumor Clinical Trials Near You

A Double-Blind Phase II Randomized Study of Adaptively Delivered LINAC-Based Stereotactic Radiation for Volatile Brain Metastases With Same-Day Planning and Margin Reduction

Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The intent of this shorter time interval is to increase the likelihood that the brain metastases being treated remain fully within the high-dose radiation fields. Participants will be randomized to receive brain-directed stereotactic radiation with a 1mm margin or 0mm margin, have their simulation/radiation planning imaging on the same day that brain-directed stereotactic radiation is delivered, and have repeat simulation/radiation planning scans during the course of treatment if more than 2-3 days have elapsed since the most recent scans.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Participants must have a biopsy proven solid malignancy with at least one intact, residual or recurrent, intracranial lesion radiographically consistent with or pathologically proven to be a brain metastasis meeting one of the following criteria:

‣ Growth of 1.0mm per week or more, on average, based on the two most recent brain MRIs preceding study enrollment

⁃ Abutment, to within 1.0cm, of a region of intracranial edema

⁃ Proximity (within 5.0cm) to a surgical cavity created within 30 days of enrollment

⁃ Proximity (within 5.0cm) to another source of physical displacement

• Age of at least 18 years

• Karnofsky performance status of at least 60

• Estimated survival of at least 3-6 months in the opinion of the enrolling clinician and/or study PI

• Ability to understand and the willingness to sign a written informed consent document by either ink on paper or a DF/HCC approved eConsent medium

Locations
United States
Massachusetts
Brigham and Women's Hospital / Dana-Farber Cancer Institute
RECRUITING
Boston
Contact Information
Primary
Ayal A Aizer, MD, MHS
aaaizer@partners.org
(617) 732-7560
Backup
Ivy B Ricca, BA
iricca@mgb.org
(617) 582-8927
Time Frame
Start Date: 2025-12-30
Estimated Completion Date: 2029-09
Participants
Target number of participants: 60
Treatments
Experimental: 0mm PTV
0mm uncertainty margin
Active_comparator: 1mm PTV
1mm uncertainty margin
Sponsors
Leads: Ayal A. Aizer, MD
Collaborators: Varian, a Siemens Healthineers Company

This content was sourced from clinicaltrials.gov